Alnylam Pharmaceuticals (ALNY) Aktienübersicht
Alnylam Pharmaceuticals, Inc. erforscht, entwickelt, produziert und vermarktet Therapeutika auf der Basis von Ribonukleinsäure-Interferenz in den Vereinigten Staaten, Europa und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für ALNY festgestellt.
ALNY Community Fair Values
Create NarrativeSee what 62 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alnylam Pharmaceuticals, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$298.76 |
| 52-Wochen-Hoch | US$495.55 |
| 52-Wochen-Tief | US$273.11 |
| Beta | 0.27 |
| 1 Monat Veränderung | 2.59% |
| 3 Monate Veränderung | -7.25% |
| 1 Jahr Veränderung | -5.14% |
| 3 Jahre Veränderung | 51.58% |
| 5 Jahre Veränderung | 68.28% |
| Veränderung seit IPO | 4,871.05% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jul 09
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook
Summary Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZeneca’s eplontersen, as it removes a key competitor in the ATTR-CM space. ALNY’s Amvuttra is positioned to capture potential billions in peak revenue previously modeled for Wainua, though better stabilizer performance may temper first-line and long-term combo usage. One less competitor in the ATTR-CM space is a positive, but the CARDIO-TTRansform could point to some elevated risks for ALNY's own Phase III TRITON-CM study of nucresiran. Upcoming Phase I/II readouts for ALN-6400, ALN-HTT02, and ALN-2232 could drive renewed Street enthusiasm and add 5% or more to fair value estimates. I raise my fair value estimate for ALNY from $450 to nearly $490, maintaining a bullish stance despite ongoing biotech risks and competitive threats. Read the full article on Seeking Alpha
Narrativ-Update • Jun 30
ALNY: Cardiomyopathy Expansion And AI Partnerships Will Drive Long Term Upside
Alnylam Pharmaceuticals' analyst-derived fair value estimate has been revised from $491.92 to $434.72 as analysts temper revenue growth and margin assumptions, following mixed adjustments to price targets and updated views on the Amvuttra launch and TTR franchise trajectory. Analyst Commentary Recent commentary on Alnylam Pharmaceuticals shows a mix of optimism around the long term potential of the TTR franchise and more cautious views on execution and valuation in the near term.
Narrativ-Update • Jun 16
ALNY: TTR Franchise Execution And 2030 Plan Will Support Stock Repricing
The analyst price target for Alnylam Pharmaceuticals has been adjusted to $550. This move reflects updated views on fair value, growth assumptions, and profitability, while aligning with recent Street commentary that highlights both the pullback in the stock and ongoing expectations around Amvuttra's launch and competitive pressures.Recent updates
Seeking Alpha • Jul 09
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook
Summary Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZeneca’s eplontersen, as it removes a key competitor in the ATTR-CM space. ALNY’s Amvuttra is positioned to capture potential billions in peak revenue previously modeled for Wainua, though better stabilizer performance may temper first-line and long-term combo usage. One less competitor in the ATTR-CM space is a positive, but the CARDIO-TTRansform could point to some elevated risks for ALNY's own Phase III TRITON-CM study of nucresiran. Upcoming Phase I/II readouts for ALN-6400, ALN-HTT02, and ALN-2232 could drive renewed Street enthusiasm and add 5% or more to fair value estimates. I raise my fair value estimate for ALNY from $450 to nearly $490, maintaining a bullish stance despite ongoing biotech risks and competitive threats. Read the full article on Seeking AlphaNarrativ-Update • Jun 30
ALNY: Cardiomyopathy Expansion And AI Partnerships Will Drive Long Term Upside
Alnylam Pharmaceuticals' analyst-derived fair value estimate has been revised from $491.92 to $434.72 as analysts temper revenue growth and margin assumptions, following mixed adjustments to price targets and updated views on the Amvuttra launch and TTR franchise trajectory. Analyst Commentary Recent commentary on Alnylam Pharmaceuticals shows a mix of optimism around the long term potential of the TTR franchise and more cautious views on execution and valuation in the near term.Narrativ-Update • Jun 16
ALNY: TTR Franchise Execution And 2030 Plan Will Support Stock Repricing
The analyst price target for Alnylam Pharmaceuticals has been adjusted to $550. This move reflects updated views on fair value, growth assumptions, and profitability, while aligning with recent Street commentary that highlights both the pullback in the stock and ongoing expectations around Amvuttra's launch and competitive pressures.
Narrativ-Update • Jun 02
ALNY: Fair View Balances ATTR-CM Data Progress With Competition And Pipeline Execution
Alnylam Pharmaceuticals' analyst fair value estimate has edged down by about $1 to $310.31, as analysts balance slightly softer modeled revenue growth and a marginally higher discount rate with a stronger profit margin outlook and ongoing support from recent price target moves and coverage initiations. Analyst Commentary Street research on Alnylam Pharmaceuticals currently reflects a mix of optimism on the drug pipeline and caution on how much of that potential is already reflected in the share price.Narrativ-Update • May 11
ALNY: Fair View Weighs TTR Execution Risks Against Cardiovascular Pipeline Progress
Analysts have nudged Alnylam Pharmaceuticals' fair value estimate to $311.72 from $310.00, reflecting updated assumptions for slightly lower revenue growth and profit margins, as well as a higher future P/E multiple based on recent shifts in price targets and commentary across the Street. Analyst Commentary Recent research has highlighted a mixed backdrop for Alnylam Pharmaceuticals, with some firms revising targets higher on product execution while others voice concern that the stock already reflects optimistic outcomes.Narrativ-Update • Apr 20
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.Narrativ-Update • Apr 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.Narrativ-Update • Mar 23
ALNY: TTR Franchise Momentum Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' updated analyst price targets show a wide reset across the Street, with cuts from firms now clustered around the $249 to $570 range. Analysts are balancing strong Amvuttra momentum and the RNAi platform's potential with concerns that the shares had been priced for very optimistic growth and competition assumptions.Narrativ-Update • Mar 07
ALNY: TTR Execution Will Support Confidence In 2026 Revenue Outlook
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals by $14 to $566, reflecting higher discount rates and more conservative assumptions for revenue growth and profit margins, even as they continue to highlight strong Amvuttra traction and supportive 2026 guidance in recent research. Analyst Commentary Recent research paints a mixed picture on valuation, but there is still a clear cluster of optimistic views around Alnylam's execution, especially in its TTR franchise and Amvuttra rollout.Narrativ-Update • Feb 21
ALNY: Fair View Weighs TTR Franchise Guidance Against Launch Execution Risks
The updated analyst price target for Alnylam Pharmaceuticals has decreased by about $45 per share, as analysts refresh their models with slightly softer revenue growth assumptions, a modestly higher long-term profit margin, and a reduced future P/E multiple. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed backdrop, with several firms revisiting their models following Q4 results, preannounced revenue figures, and updated 2026 guidance.Narrativ-Update • Feb 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Guidance
Analysts have trimmed their average price targets on Alnylam Pharmaceuticals by roughly $35 to $70, largely reflecting updated views on Amvuttra revenue trajectories, competitive pressures in ATTR-CM and recent guidance that, while still supported by continued TTR franchise momentum, has prompted more measured growth assumptions. Analyst Commentary Recent research updates show a mixed but generally constructive tone on Alnylam, with several bullish analysts pointing to execution on the TTR franchise, early Amvuttra traction in ATTR-CM and management guidance as key supports for valuation.Narrativ-Update • Jan 23
ALNY: TTR Franchise Momentum Will Drive 2026 Revenue Guidance Confidence
Narrative Update: Alnylam Pharmaceuticals Price Target Revision The analyst price target for Alnylam Pharmaceuticals has been raised by $10 to $580, as analysts weigh mixed target changes across the Street alongside company guidance that highlights ongoing momentum in the TTR franchise and a positive outlook for revenue driven by Amvuttra. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has been active, with several price target revisions and fresh commentary following the company’s Q3 results, preliminary Q4 figures, and updated 2025 and 2026 revenue guidance.Narrativ-Update • Jan 09
ALNY: Fair View Balances TTR Guidance Upside And Launch Deceleration Risk
Alnylam Pharmaceuticals' analyst fair value estimate has been raised from about $259.89 to about $368.22, as analysts factor in stronger modeled revenue growth, higher projected profitability, and a reset to more moderate future P/E expectations following recent research updates around Amvuttra uptake and revised TTR guidance. Analyst Commentary Recent research on Alnylam highlights a mixed backdrop.Narrativ-Update • Dec 26
ALNY: Cardiomyopathy Launch Will Drive Future Upside Despite Growing Competitive Pressures
Analysts have modestly lifted their price target for Alnylam Pharmaceuticals, reflecting stronger Amvuttra driven TTR revenue expectations and a series of Street target increases into the mid 400s to mid 500s, even as they highlight a more balanced risk and the potential for range bound trading into 2026. Analyst Commentary Recent Street research reflects a constructive but increasingly balanced view on Alnylam, with multiple firms lifting price targets into the mid 400s to mid 500s on the back of stronger Amvuttra traction and higher TTR revenue expectations, while also flagging valuation and competitive considerations that could cap upside.Narrativ-Update • Dec 12
ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition
Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.Narrativ-Update • Nov 27
ALNY: Future Momentum In Cardiomyopathy Will Meet Rising Competition And Pricing Pressures
The analyst price target for Alnylam Pharmaceuticals has increased by approximately $9 to $489, as analysts cite strong Amvuttra sales, raised revenue guidance, and resilient commercial momentum as key factors supporting a more optimistic outlook. Analyst Commentary Analysts have provided a range of perspectives following Alnylam Pharmaceuticals’ recent performance, with several raising their price targets and highlighting both catalysts and areas of caution for the company’s outlook.Narrativ-Update • Nov 12
ALNY: Momentum In Cardiomyopathy Segment Will Face Intensifying Competitive Risks Ahead
Alnylam Pharmaceuticals’ fair value estimate has increased from $467.94 to $480.17. This change reflects analysts' optimism about robust Amvuttra sales, raised revenue guidance, and an improved profit margin outlook.Narrativ-Update • Oct 29
Cardiomyopathy Launches And Pipeline Expansion Will Sustain Momentum Into 2025
Analysts have increased their price target for Alnylam Pharmaceuticals by approximately $16, citing stronger than expected product launches and continued commercial momentum. Analyst Commentary Following a series of upward price target revisions, Wall Street analysts remain broadly upbeat about Alnylam Pharmaceuticals’ near-term commercial performance and long-term prospects.Narrativ-Update • Oct 14
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals' analyst price targets have recently moved higher, with analysts citing stronger commercial performance of Amvuttra and encouraging data from pipeline assets as drivers behind the upward revisions. The cited targets have climbed by as much as $55 to $583 per share.Narrativ-Update • Sep 23
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.Narrativ-Update • Sep 08
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam’s modestly lower consensus price target to $421.20 reflects both strong near-term Amvuttra uptake in ATTR-CM and positive revenue outlook, tempered by mixed KARDIA-3 data for zilebesiran and resulting slight valuation adjustment. Analyst Commentary Bullish analysts cited strong commercial performance and encouraging uptake for Amvuttra, particularly following its approval and launch in ATTR-CM (transthyretin amyloid cardiomyopathy), as a key driver for raising price targets.Analyseartikel • Aug 01
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Mar 21
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Summary Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. Alnylam's proven R&D engine and above-average success ratio make it a compelling long-term biotech investment despite arguably modest immediate upside. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Alnylam: Waiting For Regulatory Updates In March
Summary Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows. Alnylam expects non-GAAP operating profitability in 2025. Successful regulatory approvals and strong commercial execution could push Alnylam's share price to new all-time highs within 6–12 months. Read the full article on Seeking AlphaSeeking Alpha • Oct 27
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Summary Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market. Regulatory risks and competition exist, but ALNY's innovative RNAi platform and experienced team position it well for sustained success. Despite a high valuation, ALNY's positive cash flow and projected revenue growth justify a "Buy on dips" strategy for long-term investors. Read the full article on Seeking AlphaAktionärsrenditen
| ALNY | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -4.5% | -2.4% | 0.7% |
| 1Y | -5.1% | 35.9% | 20.6% |
Rendite im Vergleich zur Industrie: ALNY unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 35.9% erzielte.
Rendite vs. Markt: ALNY hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.6 erzielte.
Preisvolatilität
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: ALNY hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ALNYDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2002 | 2,500 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc. erforscht, entwickelt, produziert und vermarktet Therapeutika auf der Basis von Ribonukleinsäure-Interferenz in den Vereinigten Staaten, Europa und international. Das Unternehmen bietet ONPATTRO für hereditäre Transthyretin-vermittelte (hATTR) Amyloidose, AMVUTTRA für ATTR- und hATTR-Amyloidose, Leqvio für Hypercholesterinämie, Qfitlia für Hämophilie A oder B, GIVLAARI für akute hepatische Porphyrie und OXLUMO für primäre Hyperoxalurie Typ 1. Darüber hinaus entwickelt das Unternehmen eine Reihe von Produkten in Phase-3-Studien, wie Nucresiran gegen ATTR-Amyloidose, Zilebesiran gegen Bluthochdruck, Cemdisiran gegen Myasthenia gravis, paroxysmale nächtliche Hämoglobinurie und geografische Atrophie und Elebsiran gegen Hepatitis-D-Virus-Infektionen.
Alnylam Pharmaceuticals, Inc.'s Grundlagenzusammenfassung
| ALNY grundlegende Statistiken | |
|---|---|
| Marktanteil | US$41.76b |
| Gewinn(TTM) | US$537.99m |
| Umsatz(TTM) | US$4.29b |
74.1x
Kurs-Gewinn-Verhältnis 9.3x
Kurs-Umsatz-VerhältnisIst ALNY zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ALNY Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$4.29b |
| Kosten der Einnahmen | US$821.95m |
| Bruttogewinn | US$3.46b |
| Sonstige Ausgaben | US$2.93b |
| Gewinn | US$537.99m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 4.03 |
| Bruttomarge | 80.83% |
| Nettogewinnspanne | 12.55% |
| Schulden/Eigenkapital-Verhältnis | 251.7% |
Wie hat sich ALNY auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/10 04:34 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Alnylam Pharmaceuticals, Inc. wird von 56 Analysten beobachtet. 25 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Emily Bodnar | Berenberg |